vs
Side-by-side financial comparison of NovaBay Pharmaceuticals, Inc. (NBY) and AIRWA INC. (YYAI). Click either name above to swap in a different company.
NovaBay Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($4.8M vs $3.0M, roughly 1.6× AIRWA INC.). AIRWA INC. runs the higher net margin — -7.4% vs -25.5%, a 18.1% gap on every dollar of revenue. On growth, AIRWA INC. posted the faster year-over-year revenue change (729.8% vs 126.1%). Over the past eight quarters, NovaBay Pharmaceuticals, Inc.'s revenue compounded faster (42.5% CAGR vs 14.3%).
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis
Flying W Airways (FWA) was a briefly high-profile publicly-traded company of the late 1960s/early 1970s, which originated in 1961 when its founders opened Flying W Airport in New Jersey as a fly-in resort. FWA became a bet on Alaskan oil and at its peak in 1969 attracted investment by the Matlack family, had two Hollywood actors on its board and bought Red Dodge Aviation (RDA) of Alaska, for which it acquired Lockheed L-100 Hercules aircraft, to take advantage of forthcoming Alaska pipeline c...
NBY vs YYAI — Head-to-Head
Income Statement — Q4 FY2024 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $4.8M | $3.0M |
| Net Profit | $-1.2M | $-221.8K |
| Gross Margin | 65.2% | 75.2% |
| Operating Margin | -37.2% | 1.8% |
| Net Margin | -25.5% | -7.4% |
| Revenue YoY | 126.1% | 729.8% |
| Net Profit YoY | 70.5% | 83.8% |
| EPS (diluted) | — | $-0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $3.0M | ||
| Q3 25 | — | $3.0M | ||
| Q2 25 | — | $3.0M | ||
| Q1 25 | — | $3.3M | ||
| Q4 24 | $4.8M | $3.3M | ||
| Q3 24 | $0 | $3.3M | ||
| Q2 24 | $2.4M | $-701.1K | ||
| Q1 24 | $2.6M | — |
| Q4 25 | — | $-221.8K | ||
| Q3 25 | — | $1.3M | ||
| Q2 25 | — | $552.2K | ||
| Q1 25 | — | $-411.2K | ||
| Q4 24 | $-1.2M | $-1.4M | ||
| Q3 24 | $-1.2M | $-4.2M | ||
| Q2 24 | $-1.6M | — | ||
| Q1 24 | $-3.2M | — |
| Q4 25 | — | 75.2% | ||
| Q3 25 | — | 75.2% | ||
| Q2 25 | — | 75.2% | ||
| Q1 25 | — | 77.3% | ||
| Q4 24 | 65.2% | 77.3% | ||
| Q3 24 | — | 77.3% | ||
| Q2 24 | 66.3% | — | ||
| Q1 24 | 68.2% | — |
| Q4 25 | — | 1.8% | ||
| Q3 25 | — | 49.7% | ||
| Q2 25 | — | 42.7% | ||
| Q1 25 | — | 16.2% | ||
| Q4 24 | -37.2% | 71.2% | ||
| Q3 24 | — | 74.6% | ||
| Q2 24 | -67.4% | — | ||
| Q1 24 | -87.1% | — |
| Q4 25 | — | -7.4% | ||
| Q3 25 | — | 42.0% | ||
| Q2 25 | — | 18.4% | ||
| Q1 25 | — | -12.6% | ||
| Q4 24 | -25.5% | -41.7% | ||
| Q3 24 | — | -129.0% | ||
| Q2 24 | -66.0% | — | ||
| Q1 24 | -122.2% | — |
| Q4 25 | — | $-0.05 | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-1.41 | ||
| Q4 24 | — | $6.43 | ||
| Q3 24 | $-1.92 | $-1.91 | ||
| Q2 24 | $-1.37 | $-30.98 | ||
| Q1 24 | $-29.95 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $430.0K | $107.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-129.0K | $165.4M |
| Total Assets | $3.4M | $172.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $107.0M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | — | $1.4M | ||
| Q1 25 | — | $4.3M | ||
| Q4 24 | $430.0K | $18.1M | ||
| Q3 24 | $776.0K | $18.2M | ||
| Q2 24 | $751.0K | $1.8M | ||
| Q1 24 | $1.8M | — |
| Q4 25 | — | $165.4M | ||
| Q3 25 | — | $26.2M | ||
| Q2 25 | — | $25.3M | ||
| Q1 25 | — | $26.1M | ||
| Q4 24 | $-129.0K | $8.0M | ||
| Q3 24 | $1.1M | $9.4M | ||
| Q2 24 | $-617.0K | $9.6M | ||
| Q1 24 | $160.0K | — |
| Q4 25 | — | $172.1M | ||
| Q3 25 | — | $34.7M | ||
| Q2 25 | — | $32.9M | ||
| Q1 25 | — | $30.7M | ||
| Q4 24 | $3.4M | $21.6M | ||
| Q3 24 | $3.9M | $23.2M | ||
| Q2 24 | $3.9M | $23.2M | ||
| Q1 24 | $5.4M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-30.8M |
| Free Cash FlowOCF − Capex | $-1.7M | — |
| FCF MarginFCF / Revenue | -35.4% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-30.8M | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | — | $-423.7K | ||
| Q1 25 | — | $-133.8K | ||
| Q4 24 | $-1.7M | $779.4K | ||
| Q3 24 | $-2.4M | $-601.3K | ||
| Q2 24 | $-1.4M | $-460.3K | ||
| Q1 24 | $-2.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-2.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -35.4% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -75.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.86× | ||
| Q2 25 | — | -0.77× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NBY
| Other | $2.4M | 51% |
| Total Product Revenue | $2.3M | 49% |
YYAI
Segment breakdown not available.
